Skip to main content
European Commission logo print header

Tiam1-Rac signalling in lymphomagenesis

Objective

Background: Retrovirus-induced tumours acquire in time increasing numbers of proviruses in their genome, which are required for the activation of additional (onco)-genes that contribute to tumour progression.

Insertional mutagenesis in oncogene-bearing transgenic mice is therefore a powerful strategy to identify genes that cooperate with the transgene in the formation and progression of tumours.

In the host lab, the Tiam1 gene was identified by retroviral insertional mutagenesis in combination with selection for invasive T-lymphoma cells. The Tiam1 gene was also frequently activated (>70%) in T-lymphomas induced by retroviral infection of tumour-prone transgenic Em-Pim1 mice.

Tiam1 thus seems to play a critical role in the initiation and progression of T-lymphomas. Tiam1 encodes an activator of the Rho-like GTPase Rac. Rho-GTPases regulate a wide variety of cellular processes including cytoskeletal rearrangements, cell migration, and gene transcription.

Objectives: In this proposal we want to uncover the signalling pathways that act downstream or parallel of Tiam1and that are essential for lymphomagenesis in vivo. To this end, we propose to perform an insertional mutagenesis screen on tumour-prone transgenic Eµ-Pim1 mice in a Tiam1-deficient background.

Strategy: T-lymphomas will be induced in Tiam1-deficient Eµ-Pim1 mice by Moloney Murine Leukemia virus (M-MuLV) infection. Targeted genes will be identified using improved Splinkerette PCR. The sequence data will be mapped and used to identify common insertion sites. The involvement of the gene targets in lymphomagenesis will be confirmed by in vitro and in vivo analyses.

Results: The obtained results are expected to give insight into the downstream signalling pathways of Tiam that are acting in the development and progression of lymphomas in vivo. These gene products may turn out to be targets for the development of diagnostic tools or novel anti-cancer therapies.

Call for proposal

FP6-2002-MOBILITY-5
See other projects for this call

Coordinator

THE NETHERLANDS CANCER INSTITUTE DIVISION OF CELL BIOLOGY
Address


Netherlands

See on map

EU contribution
€ 0,00